Disease modification in psoriasis through early interleukin 17 inhibitor intervention: A retrospective cohort study - 18/09/25
, Chengzhi Lv, PhD f, ⁎ , Yehong Kuang, PhD a, b, c, d, e, ⁎ Abstract |
Background |
Although interleukin (IL) 17 inhibitors like secukinumab and ixekizumab have shown significant efficacy in psoriasis, the impact of early intervention with biologics to modify the disease course and achieve long-term remission remains unclear.
Objectives |
To examine the potential of early intervention with IL-17 inhibitors for disease modification in psoriasis.
Methods |
We conducted a multicenter retrospective cohort study on moderate-to-severe plaque psoriasis patients who received at least 4 weeks of treatment with secukinumab or ixekizumab between April 2019 and April 2023, taking the relapse rate 1 year after cessation of treatment as the primary endpoint.
Results |
Among 400 patients who discontinued treatment after achieving Psoriasis Area and Severity Index 90, the median relapse time was 3.29 months (approximately 14 weeks). Of 141 patients who discontinued treatment after achieving Psoriasis Area and Severity Index 90 for over a year, 24 (88.89%) in the ultra-short disease duration (psoriasis duration ≤1 year) group and 33 (82.5%) in the short disease duration (psoriasis duration ≤2 years) group achieved 1 year of drug-free remission.
Limitations |
The potential impact of early intervention on comorbidity development was not addressed in this study.
Conclusion |
Early intervention with IL-17 inhibitors leads to faster responses and may promote disease modification in psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : disease modification, early intervention, IL-17 inhibitor, ixekizumab, psoriasis, secukinumab
Abbreviations used : BSA, DLQI, LDD, PASI, PGA, SDD, USDD
Plan
| Drs Chen, Sha, and Author Zhou contributed equally to this work. |
|
| Funding sources: This research was funded by the National Key Research and Development Program of China (2023YFC2508105), the Hunan Provincial Natural Science Foundation Youth Fund (no. 2021JJ40970), and the National Natural Science Foundation of China (82373484, 82073447, 82003354, 82221002, 82130090, and 82003362). |
|
| Patient consent: All of the recruited patients voluntarily participated and signed the informed consent forms. Before participation, all patients had provided written informed consent either confirmed by themselves (adults) or approved by their parents or legal guardians (those under 18). |
|
| IRB approval status: The procedures of this study were conducted in accordance with the 1964 Helsinki Declaration and subsequent amendments or similar ethical standards. This study has been approved by the Ethics Committee of Xiangya Hospital, Central South University (ethical approval number: 2018121106). |
|
| Data availability: All data have been provided with the manuscript and supplementary material and are presented in the form of graphs in the text. For more information about resources, it should be contacted to the lead contact, Yehong Kuang (yh_927@126.com). |
Vol 93 - N° 4
P. 1000-1007 - octobre 2025 Retour au numéro
Article précédent
- Antidepressant usage and its postoperative outcomes on the surgical management of basal cell carcinomas: A propensity-matched cohort analysis
- Nehaa Sohail, Ayaan Sohail, Amir Alsaidi, Matthew Dallo, Misha V. Koshelev
- Global, regional, and national burdens of atopic dermatitis from 1990 to 2021: A trend analysis from the Global Burden of Disease Study 2021
- Chen Sun, Xuan Zhang, Zheng Su, Wen-Hui Yao, Hong-Da Chen, Yue-Ping Zeng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?